In this article, John McDermott, Vice President of Scientific Consulting at Quotient Sciences talks about how AI Drives 50% Faster Formulation Development.
Quotient Sciences is leveraging advanced AI and Machine Learning techniques to dramatically accelerate formulation development, achieving reductions in timelines of up to 50%.
While AI enhances speed and decision‑making, human expertise remains central to ensuring scientific rigor, regulatory compliance, and reliable interpretation. Through partnerships like its recent collaboration with Intrepid Labs and the integration of the Andromeda AI platform, Quotient Sciences continues to advance data‑driven, human‑guided innovation across early drug development.
Continue reading the full article on Drug Development & Delivery.